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1. Introduction 
The surface of the human gut has a surplus area of 200-250 m2 in order to contain, between 
intraepithelial lymphocytes and lamina propria, Peyer’s patches and lymphoid follicles, the 
lymphoid tissue, while hosts a flora of about 800 different bacteria species with over 7000 
strains. The 99% are obligate anaerobes and varies species were then classified using 
traditional anaerobic culture techniques. More than 50% of the dominant gut microbiota 
(corresponding to 10 8-10 11 per gram of faeces) cannot be identified using traditional colture 
,but molecular approaches, based on the use of 165 ribosomal DNA molecular (Mai & 
Morris, 2004). Most of these bacteria colonizes the large intestine (in a range of 10-12 
bacteria/g). The bacterial count of the small intestine (duodedum and jejunum) is 
considerably lower (approximately 104-7 bacteria/ml) than Streptococcus Lactobacillus, 
Enterobacteriaceae corresponding to the transient microbiota. 
The main bacterial species represented in the human large intestine (colon) are distributed 
with densities higher than 10 9-11 per gram of contents, and these high densities can be 
explained by the slow transit and low redox potential . In this intestinal tract we can mostly 
find bifidobacteria and bacteroides ,bifidobacterium clostridium. The fecal microbiota 
contains 10 9 _10 11 CFU per gram, and microorganism in about 40% of their weight. The 
dominant microbiota is represented by strict anaerobes , while the sub-dominant microbiota 
by facultative anaerobes. In addition to the resident microbiota (dominant and sub 
dominant), the faeces contain the transient microbiota, that is extremely variable, including 
Enterobacteriacee (Citrobacter, Klebsiella, Proteus ) and Enterobacter (Pseudomonas) and 
yeast ( Candida) CFU per gram (Table 1) (Zoetendal et al, 2004). 
2. Intestinal microbiota in newborn 
The normal human microflora is a complex ecosystem that somehow depends on enteric 
nutrients for establishing colonization. At birth ,the digestive tract is sterile. This balance of 
the intestinal microflora is similar to that of adult from about two years of age (Hammerman 
et al, 2004). 
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Mouth 200 species  
Stomach,duodenum pH 2,5-3,5 destructive to most of 
bacteria 101_103 unit /ml 
Lactobacillus,Streptococcus, 
 
Jejunum,ileum 10 4_ 10 6 unit /ml bifidobacteria and 
bacteroides ,bifidobacterium 
clostridium 
Aerobes 
Colon 300-400 several species 1010_ 1011 unit 
/ml 
Enterobacteriacee (Citrobacter, 
Klebsiella,Proteus)o(Pseudomonas) 
Candida. 
Anaerobes 
Table 1. Composition and topographical features of intestinal microbiota 
Diet and environmental conditions can influence this ecosystem. At birth intestinal 
colonization derives from microorganism of the vaginal mucoses of the mother and faecal 
microflora . The microbial imprinting depends on the mode and location of delivery. 
Literature data shows that infants born in a hospital environment, by caesarean section, have a 
high component of anaerobic microbial flora (Clostridia) and high post of Gram-negative 
enterobacteria. Those born prematurely by vaginal delivery and breast-feed have a rather rich 
in Lactobacilli and Bifidobacteria microflora. (Grönlund et al, 1999; Hall et al, 1990) 
Diet can influence the microbiota, while breast-feeding promotes an intestine microbiota in 
which Bifidobacteria predominate, while coliform, enterococci and bacteroides predominate 
in formula bottle-fed baby.  
Escherichia coli and Streptococcus are included among the first bacteria to colonize the 
digestive tract. After them, strict anaerobes (Bacteroides, Bifidobacteri ,Clostridium) 
establish during the first week of life, when the diet plays a fundamental role. (Mackie et al, 
1999). The pattern of bacterial colonization in the premature neonatal gut is different from 
the one of healthy, full term infant gut. Aberrant pre-term infants admitted to NICU, born 
by caesarean section, are more often separated from their mother and kept in an aseptic 
intensive care setting, treated with broad-spectrum antibiotics. This is the reason why they 
show a highly modified bacterial flora, consisting of less than 20 species of bacteria, with a 
predominance of Staphylococcus (aureus and coagulase negative) among aerobic micro-
organisms, and Enterobacteriaceae (Klebsiella), among enterococci and anaerobic Clostridia 
(Dai et al, 1999; Gothefor, 1989). 
It is believed that microbial diversity is an important factor in determining the stability of 
the ecosystem and that the fecal loss of diversity predisposes the preterm gastrointestinal 
colonization of antibiotic-resistant bacteria and fungi colonization with a consequent 
potential risk of infection, thus contributing to the development of necrotizing enterocolitis 
(NEC) (Fanaro et al, 2003; Sakata et al, 1985) 
2.1 Structure and function of intestinal microbial flora 
The intestinal microbial flora has numerous functions, even if the most of them has not yet 
been identified. Among these functions, we can report its anatomical –functional role, its 
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protective function, in particular the “barrier effect”, referring to the physiological capacity 
of the endogenous bacterial microflora to inhibit colonization of the intestine by pathogenic 
microorganism. It is already known that the intestinal microbial flora influences food 
digestion ,absorption and fermentation, the immune system response, peristalsis, 
production of vitamins such as B-vitamins, influencing moreover the turnover of intestinal 
epithelial cells. In addition the metabolism of gut microflora influences hormonal secretion. 
Bacterial colonization of human gut by environmental microbes begins immediately after 
birth; the composition of intestinal microbiota, relatively simple in infants, becomes more 
complex with increasing in age, with a high degree of variability among human individuals. 
It is believed that microbial diversity is an important factor in determining the stability of 
the ecosystem and that fecal loss of diversity predisposes the preterm gastrointestinal 
colonization of antibiotic-resistant bacteria and fungi with the consequent potential risk of 
infection (Cummings & Macfarlane, 1991; Montalto et al, 2009; Neish, 2002). 
2.2 Gut microflora and immunity 
The mucosal membrane of the intestines, with an area of approximately 200 m2, is 
constantly challenged by the enormous amount of antigens from food, from the intestinal 
microbial flora and from inhaled particles that also reach the intestines. It is not surprising 
therefore that approximately the eighty per cent of the immune system is found in the area 
of the intestinal tract and it is particularly prevalent in the small intestine. The intestinal 
immune system is referred as GALT (gut-associated-lymphoid tissue). It consists of Peyer’s 
patches, which are units of lymphoid cells, single lymphocytes scattered in the lamina 
propria and intraepithelial lymphocytes spread in the intestinal epithelia. 
The immune system of infants is not fully developed. The structures of the mucosal immune 
system are fully developed in utero by 28 weeks gestation, but in the absence of intrauterine 
infections, activation does not occur until after birth. Maturation of the mucosal immune 
system and establishment of protective immunity is usually fully developed in the first 
years of life. In addition the exposure to pathogenic and commensal bacteria, the major 
modifier of the development patterns in the neonatal period, depends on infant feeding 
practices. (Brandtzaeg, 2001; Gleeson et al, 2004) 
Bacterial colonisation of the intestine is important for the development of the immune 
system. The intestine has an important function in working as a barrier.This barrier is 
maintained by tight-junctions between the epithelial cells, by production of IgA antibodies 
and by influencing the normal microbial flora. It is extremely important that only harmless 
substances are absorbed while the harmful substances are secreted via the faeces. 
Studies show that individuals allergic to cow´s milk have defective IgA production and an 
increased permeability of the intestinal mucosa. This results in an increased absorption of 
macromolecules by the intestinal mucosa. The increased permeability is most probably 
caused by local inflammations due to immunological reactions against the allergen. This 
damages the intestinal mucosa 
2.3 Modification of the intestinal flora micro-ecosystem 
During the past century our lifestyle has dramatically changed regarding hygienic 
measures, diet, standards of living and usage of medical drugs. Today our diet largely 
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includes industrially produced sterilized food and the use of different kinds of 
preservatives. This has led to a decreased intake of bacteria, particularly lactic acid 
producing bacteria . 
The widespread use of antibiotics in healthcare and agriculture, antibacterial substance is 
also something new for human kind. We have in so many ways sterilized our environment, 
which is detrimental to the microbial (Cummings & Macfarlane G.T., 1997; Vanderhoof & 
Young, 1998). 
3. What are probiotics? 
The term ‘probiotic’ was proposed in 1965 to denote an organism or substance that 
contributes to the intestinal microbial balance. The definition of probiotics has subsequently 
evolved to emphasise a beneficial effect to health over effects on microbiota composition, 
underscoring the requirement of rigorously proven clinical efficacy. Most probiotic bacterial 
strains were originally isolated from the intestinal microbiota of healthy humans and the 
probiotics most thoroughly investigated thus far belong to the genera lactobacilli and 
bifidobacteria (Caramia G., 2004). 
Probiotics have several effects, including modulating the gut microbiota, promoting 
mucosal barrier functions, inhibiting mucosal pathogen adherence and interacting with the 
innate and adaptive immune systems of the host, which may promote resistance against 
pathogens. The intestinal microbiota constitutes an important aspect of the mucosal barrier 
the function of which is to restrict mucosal colonisation by pathogens, to prevent pathogens 
from penetrating the mucosa and to initiate and regulate immune responses 
3.1 Proved beneficial effects on the host 
Prerequisites for probiotics’ efficacy are human origin, resistance transit gastric capacity to 
colonize survival in and adhesion, competitive exclusion of pathogens or harmful antigens 
to specific areas of the gastrointestinal tract, vitality, verifiable and stability conservation, 
production substances with antimicrobial action, exclusion of resistance transferable 
antibiotic. No pathogenicity and / or toxicity has ever been demonstrated on the host. 
3.2 Effect of probiotics 
Among their effects, the most important are: competition to the more valid nutrients and 
enteric epithelial anchorage sites; reduction of intestinal pH values for high production of 
lactic acid from lactose and acetic acid from carbohydrates, which selects the growth of 
lactobacilli; production of bacteriocins, peptides with bactericidal activity towards related 
bacteria species; metabolism of certain nutrients in the volatile fatty acids; activation of 
mucosal immunity, with increased synthesis of secretory IgA, and phagocytosis; stimulation 
of production of various cytokines 
3.3 Mechanism of action of probiotics 
The functional interactions between bacteria, gut epithelium, gut mucosal immune system 
and systemic immune system are the basis of the mechanisms of direct and indirect effects 
of probiotics. The direct effect of probiotics in the lumen are: competition with pathogens for 
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nutrients, production of antimicrobial substances and in particular organic acids 
competitive inhibition on the receptor sites, change in the composition of mucins hydrolysis 
of toxins, receptorial hydrolisis, and nitric oxide (NO), while the indirect effect largely 
depends on the site of interaction between the probiotic and the effectors of the immune 
response, topographically located in the intestinal tract. 
There is evidence, in vitro and in vivo, on effects of different probiotics on specific 
mechanisms of the immune response. The starting point is the interaction between probiotic 
and the host intestinal mucosa, but it seems clear that not all probiotics have the same initial 
contact (immune cells, enterocytes, etc.). 
There are several literature data that have demonstrated the interaction between probiotics 
and the immune system, in particular it has been demonstrated their capacity to stimulate 
the production of intestinal mucines, their trophic effect on intestinal epithelium, the re-
establishment of the intestinal mucosa integrity, the stimulation of the IgA-mediated 
immune response against viral pathogens. All these effects have been demonstrated in 
experimental studies and in some clinical studies, even if it is not still clear the main 
mechanism of action and it is conceivable that different mechanisms of action contribute to 
the efficacy of probiotics, with a different role in different clinical situations (Vanderhoof & 
Young, 1998). 
3.4 Safety 
The oral consumption of viable bacteria in infancy naturally raises safety concerns. Products 
containing probiotics are widely available in many countries and, despite the growing use of 
such products in recent years, no increase in Lactobacillus bacteraemia has been detected. 
Nevertheless, the average yearly incidence of Lactobacillus bacteraemia in Finland between 
the years 1995 and 2000 was 0.3 cases/100,000 inhabitants. Importantly, 11 out of the 48 
isolated strains were identical to Lactobacillus GG, the most commonly used probiotic 
strain. Lactobacillus bacteraemia is considered to be of clinical significance; immune-
suppression, prior prolonged hospitalisation and surgical interventions have been identified 
as predisposing factors. Nonetheless, clinical trials with products containing both 
lactobacilli and bifidobacteria have demonstrated the safety of these probiotics in infants 
and children, and in a recent study, the use of L. casei was found to be safe also in critically 
ill children 
In a trial assessing the safety of long-term consumption of infant formula containing B. lactis 
and S. thermophilus, the supplemented formulas were demonstrated to be safe and well 
tolerated. No serious adverse effects have been reported in the trials involving premature 
neonates, but it should be noted that the studies were not primarily designed to assess their 
safety (Hammerman et al, 2006) 
4. Probiotics and gastrointestinal disorders 
The presence of Bifidobacteria in artificial milk can contribute to the induction of a 
significant increase of Bifidobacteria in the intestinal tract, promotes the development of a 
protective microflora, similar to that one of the breast- fed newborn, contributes to the 
modulation of immune-defenses, giving them a major efficiency (Langhendries et al, 1995; 
Fukushima et al, 1998). 
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In early 2002, the United States Food and Drug administration accepted a “generally 
regarded as safe (GRAS) the use of Bifidobacterium lactis and Streptococcus thermophilus in 
formula milk for healthy infants aged 4 months or more” (Hammerman et al, 2006).  
The clinical efficacy of probiotics in the prevention and treatment of infectious disease in 
infancy has most comprehensively been documented in diarrhoeal disease. Lactobacillus GG 
or Lactobacillus reuteri (ATCC 55730) supplementation has been demonstrated to be effective 
in the prevention of acute infantile diarrhoea in different settings. Lactobacillus GG has also 
been reported to significantly reduce the duration of acute diarrhoea and the duration of 
rotavirus shedding after rotavirus infection. Bifidobacteria have also shown promising 
potential in preventing both nosocomial spread of gastroenteritis and diarrhoea in infants in 
residential care settings. Meta-analyses of double-blind, placebo-controlled clinical trials 
have concluded that probiotics, particularly Lactobacillus GG, are effective in treatment of 
acute infectious diarrhoea in infants and children. Probiotics appear also to have some 
protective effect against antibiotic-associated diarrhoea and acute diarrhoea in children, but 
the heterogeneity of the available studies precludes drawing firm conclusions (Vanderhoof, 
2000). 
5. Probitics and atopic disease 
Probiotics acts on atopic diseases modulating initial colonisation, intralumenal degradation 
of allergens, promoting intestinal barrier function, enhancing immune maturation with 
induction of IgA production, induction of regulatory T cells. In infancy, food allergy and 
atopic eczema are the most common atopic disorders. Even though atopic disease often 
becomes manifest during the course of the first year of life, it is well established that the 
immune pathology leading to clinical disease has its origins in early life, possibly already in 
the immune environment prevailing in utero. Indeed, infantile food allergy could be 
considered a manifestation of a primary failure to establish tolerance to dietary antigens 
rather than loss of tolerance characteristic of allergies in later life. Therefore, measures 
aimed at reducing the risk of atopic diseases should be started in the perinatal period. Thus 
far, the rationale of most studies assessing means of primary prevention of atopic diseases 
has been to reduce exposure to the allergens known to most often be associated with 
sensitisation and provocation of symptoms in allergic individuals, but the success of such 
measures has been relatively poor. Consequently, probiotics have been investigated as a 
novel approach with a number of potential effects which might beneficially affect the host 
immune physiology to a non-atopic mode.  
The immune pathology of atopic diseases is characterised by T helper (Th)2-driven 
inflammatory responsiveness against ubiquitous environmental or dietary allergens. The 
factors leading to inappropriate Th2 responsiveness, and thus atopic disease, in early 
immune development remain poorly understood. Th2-type responsiveness is counter-
regulated both by Th1 responses, which are usually directed against infectious agents and 
immunosuppressive, and by tolerogenic regulatory T cell responses. Prescott and colleagues 
demonstrated that infants with high hereditary risk who subsequently developed atopic 
disease are characterised by an impaired capacity (compared with healthy infants) to 
produce both Th1 and Th2 cytokines in the neonatal period. During the first year of life, an 
increase in Th2 responsiveness is seen in infants developing atopic disease, whereas a 
reverse development takes place in healthy infants.  
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5.1 Use of probiotics for prevention of atopic diseases 
As previously mentioned, the sequence of bacterial intestinal colonization of neonates and 
young infants is important in the development of the immune response. Recognition by the 
immune system of self and nonself, as well as the type of inflammatory responses generated 
later in life, are likely affected by the infant’s diet and acquisition of the commensal 
intestinal bacterial population superimposed on genetic predisposition. 
During pregnancy, the cytokine inflammatory-response profile of the fetus is diverted away 
from cell-mediated immunity (T-helper 1 [Th1] type) toward humoral immunity (Th2 type). 
Hence, the Th2 type typically is the general immune response in early infancy. The risk of 
allergic disease could well be the result of a lack or delay in the eventual shift of the 
predominant Th2 type of response to more of a balance between Th1- and Th2-type 
responses (Neaville, 2003). 
Administration of probiotic bacteria during a time period in which a natural population of 
lacticacid– producing indigenous intestinal bacteria is developing could theoretically 
influence immune development toward more balance of Th1 and Th2 inflammatory 
responses (Majamaa & Isolauri, 1997). The intestinal bacterial flora of atopic children has 
been demonstrated to differ from that of nonatopic children. Specifically, atopic children 
have more Clostridium organisms and fewer Bifidobacterium organisms than do nonatopic 
study subjects ( Björkstén et al, 1999; Klliomaki et al, 2001), which has served as the rationale 
for the administration of probiotics to infants at risk of atopic diseases, particularly for those 
who are formula fed. 
In a double-blinded RCT, LGG or a placebo was given initially to 159 women during the 
final 4 weeks of pregnancy. If the infant was at high risk of atopic disease (atopic eczema, 
allergic rhinitis, or asthma), the treatment was continued for 6 months after birth in both the 
lactating woman and her infant (Kalliomäki et al, 2003). A total of 132 mother-infant pairs 
were randomly assigned to receive either placebo or LGG and treated for 6 months while 
breastfeeding. The primary study end point was chronic recurrent atopic eczema in the 
infant. Atopic eczema was diagnosed in 46 of 132 (35%) of these study children by 2 years of 
age. The frequency of atopic eczema in the LGG-treated group was 15 of 64 (23%) versus 31 
of 68 (46%) in the placebo group (RR: 0.51 [95% CI: 0.32– 0.84]; P = .01). The number of 
mother-infant pairs required to be treated with LGG to prevent 1 case of chronic recurrent 
atopic eczema was 4.5. By 4 years of age, eczema occurred in 26% of the infants in the group 
treated with LGG, compared with 46% in the placebo group (RR: 0.57 [95% CI: 0.33– 0.97]; P 
=.01). However, only 67% of the original study group was analyzed at the 4-year follow-up. 
These results support a preventive effect for giving a probiotic to mothers late in pregnancy 
and to both mothers and infants during the first 6 months of lactation for the prevention of 
atopic eczema in infants who are at risk of atopic disease.  
Conversely, Taylor et al (2007) found that probiotic supplementation did not reduce the risk 
of atopic dermatitis in children at high risk with the report of some increased risk of 
subsequent allergen sensitization. As concluded in a review by Prescott and Björkstén (2007) 
and in a 2007 Cochrane review (Osborn & Sinn, 2007) despite the encouraging results of 
some studies, there is insufficient evidence to warrant the routine supplementation of 
probiotics to either pregnant women or infants to prevent allergic diseases in childhood. 
Explanations for varied study results include host factors such as genetic susceptibility, 
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environmental factors such as geographic region and diet, and study variables including 
probiotic strains and doses used (Prescott & Björkstén, 2007; Penders, 2007). 
5.2 Use of probiotics in the treatment of atopic diseases 
In an RCT, 53 Australian infants with moderate-to-severe atopic dermatitis were given either 
Lactobacillus fermentum or placebo for 8 weeks. At final assessment at 16 weeks, significantly 
more children who received the probiotic had improved extent and severity of atopic 
dermatitis as measured by the Severity of Scoring of Atopic Dermatitis (SCORAD) index over 
time compared with those who received placebo (P = .01) (Weston et al, 2005; Viljanen et al, 
2005). These results are encouraging, but as summarized in a 2008 Cochrane review (Boyle et 
al, 2008), probiotics have not yet been proven to be effective in the treatment of eczema. 
6. Probiotics and premature infants 
Prematurity compromises the anatomical and functional development of all organs, in 
inverse proportion to the gestational age. Some peculiarities of the preterm are the high 
incidence of respiratory diseases, the multi-systemic immaturity, even if nutrition 
constitutes one of the major actual problem to afford.  
The preterm infant lacks of the sucking reflex, has a restricted gastric and intestinal capacity, 
insufficient absorption of the main food, that contribute to both quantitative and qualitative 
nutritional deficiencies.  
The lack of an adequate nutrition decreases the synthesis of surfactant and anti-oxidant 
molecules, thus causing a delayed lung maturation and both cellular and humoral immune 
response, responsible for an increase of the catabolism, promoting the use of endogenous 
proteins. Therefore, the goal of the nutrition of the ELBW infant is the manteinance of his 
post-natal growth, similarly of what happens in utero, preventing the protein catabolism 
(through the use of endogenous proteins: lean body mass), avoid the weight loss during the 
first 2 weeks after birth, assuring a high energetic rate since his first day of life, thus 
reducing the percentage of preterms with a weight less than 10° percentile at discharge.  
Nowadays the first approach to ELBW preterms is the parenteral nutrition since their first 
day of life (with the prompt introduction of glucose as it is the main source of energy and it 
reduces the catabolism of endogenous proteins since the first 2 hours after birth, and the 
introduction of lipids since the first 24 hours after birth). It is also important the introduction 
of low quantities of milk (minimal enteral feeding) via oral or nasal-gastric way in order to 
promote the feeding tolerance and the increase of enteral production of cholecystokinin that 
stimulates the bile function, protecting the liver from hepatic steatosis due to parenteral 
nutrition.  
It is important that these procedures are managed in a gradual way in order to avoid the 
tiredness of the infant and the aspiration of milk with regurgites. For this reason it is 
conceivable using a fortified maternal formula for premature infants, with a daily increase 
of the feeding, paying attention to abdominal distension, vomit, gastric stagnation, apneas, 
and diarrhea.  
It is conceivable to stop the parenteral nutrition when the energetic rate reach a quote of 
80cal/Kg/die and the daily increase of milk must not be more than 10ml/Kg/die, and 
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sometimes it is necessary the continuous or discontinuous enteral feeding, via nasal-gastric 
tube, in order to suspend the parenteral nutrition.  
The passage from enteral nutrition to nursing depends on the acquisition of sucking, 
deglutition, epiglottis and larynx closure ability and on the nasal passage, as well as the 
esophageal motility and a synchronized process is usually absent before 34 weeks of 
gestation. The sucking ability is usually reached when the infant has a weight over 1500 gr 
even if sometimes it is necessary to proceed with the tactile stimulation of the infant tongue 
(Tsang et al, 2005). 
Enzymatic digestive functions in preterm more than 28 weeks of gestation are mature 
enough to allow the adequate digestion and absorption of proteins and carbohydrates. 
Lipids are well adsorbed and unsaturated fatty acids and lipids in maternal milk are better 
adsorbed than the components of the formula milk.  
The weight gain in infants with a birth weight less than 2000 gr should be adequate when 
the mother shows a protein intake of 2.25-2.75/Kg/die, because they should provide a good 
intake of essential aminoacids, in particular tryptophan and threonine, that are important 
for the cerebral development.  
The maternal milk, through specific immunologic factors, can potentiate the defensive 
mechanisms of preterms, contributing to ameliorate the immune defense against infectious 
agents. Recent studies highlighted that the maternal milk not only promote a passive 
protection, but can directly modify the immunologic development of the infant.  
The maternal milk contains immunologic and non-immunologic factors, and immune-
modulant factors, such as the bifidogenic factor, that promotes the development of the 
Lactobacillus Bifidus, that by competition promotes the decrease of the intestinal pH and 
inhibits the growth of Escherichia Coli. The maternal milk must be fortified, while the 
formula for preterm infants do not contain the bifidogenic factor (Heiman & Schanler, 2007) . 
It is also well established that the composition of the intestinal microbiota is aberrant and its 
establishment delays in neonates who require intensive care, with an increased risk of 
developing NEC. As discussed above, probiotics have been shown to enhance the intestinal 
barrier, inhibit the growth and adherence of pathogenic bacteria and to improve altered gut 
micro-ecology In preterm infants, administration of the probiotic Lactobacillus GG has been 
shown to affect colonisation patterns. Data from experimental animal models suggest that 
bifidobacteria reduce the risk of NEC in rats. Consequently, it could be hypothesised that 
probiotics might have potential in reducing the risk of NEC in premature infants.  
The supplementation of probiotics since the first day of life represents a valid help in 
influencing the growth of a favourable intestinal ecosystem, decreasing the quote of 
Clostridium, Bacillus and Bacteroides Fragilis and increasing the rate of bifidobacteria, also 
improving the intestinal barrier with a way of action similar to that of the maternal milk, 
protecting the gut from bacteria and fungal colonization, avoiding the development of NEC. 
7. Probiotics and necrotizing enterocolitis 
Necrotizing enterocolitis (NEC) is a serious anoxic and ischemic disease particularly 
affecting premature newborns, affecting almost the ileo-colic area, with bacteria 
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proliferation, production of gas inside gastric walls (cystic pneumatosis), associated with 
edema and inflammation. Its incidence rate is 1-3 cases for 1000 newborns, with a mortality 
rate ranging between 10-50%. The prematurity is the most important risk factor, as well as 
the low birth weight (< 1500 gr). This risk increases after the colonization or the infection of 
pathogens such as Clostridium, Escherichia, Klebsiella, Salmonella, Shigella, 
Campylobacter, Pseudomonas, Streptococcus, Enterococcus, Staphylococcus aureus and 
coagulase negative Staphylococcus. Other factors that can increase its incidence are the 
intestinal immaturity, the decrease of the intestinal motility, the increase of permeability to 
macromolecules and the excessive volume of milk. Certainly breast feeding represents a 
protective factor, as it is shown by the decreased incidence of NEC in breast-fed infants. 
Moreover literature data supporting the benefits of probiotics are increasing in the last 
decades.  
The role of intestinal micro-organisms has been largely described, even if it is still not clear. 
Advances in molecular biology and intestinal microbiology allow a better characterization 
of the intestinal microbiota in children affected by NEC. Nowadays, literature data describe 
different methods of characterization of the microbic genotype and of identification of its 
genes, expression of the specific proteins and production of metabolites. The application of 
these techniques on bioptic samples of infected and non-infected subjects could better the 
comprehension of the persistence of NEC in premature newborns. Deshpande et al. (2007) 
published a meta analysis that confirms the benefit of probiotic supplements in reducing 
death and disease in preterm newborns.  
The mechanism of action of probiotics in the protection of NEC seem to be the increased 
production of anti-inflammatory cytokines, blockage of the passage of bacteria and their 
products through the mucose, competitive action with some pathogen groups, modification 
of the response of the host towards microbial products, improving the enteral nutrition, 
decreasing the duration of the parenteral nutrition, responsible for late sepsis.  
Different studies highlight that the supplementation of probiotics reduces the risk of NEC. 
In the most recent literature, the study of Bin-Nun et al. (2005) showed a lower frequency of 
serious diseases in newborns with a low birth weight when in their feeding was added a 
probiotic mixture. Desphande’s meta analysis, published in Lancet in 2007, showed the 
same results. As a matter of fact the first studies on probiotics in premature children were 
leaded in order to reduce the incidence of NEC in this group of children.  
8. Probiotics and infections 
The most valid indication of the probiotic remains the decrease of intestinal infections. In 
fact, the literature shows that the probiotic can reduce the severity and number of episodes 
of diarrhea.  
Weizman & Alsheikh made a double-blind placebo-controlled study using a formula 
supplemented with L. reuteri or B. bifidium for 12 weeks. In the group of infants in therapy 
with probiotics, less gastrointestinal infectious episodes have been detected, fewer episodes 
of fever compared to placebo, with consequent reduce of antibiotic therapy. The fetus and 
the newborn are particularly vulnerable to the injuries caused by infectious agents or 
immunological mechanisms related to the immaturity of the immune system. The 
improvement of perinatal care has led to increased survival of high-risk infant (ELBW, 
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respiratory distress, surgery), neonatal research priorities on the prevention and treatment 
of sepsis in NEC and bronchopulmonary dysplasia (CLD) (Weizman & Alsheikh, 2006).  
In view of the role of mediators of inflammation in CLD and in sepsis is therefore important 
to modulate the immune response in these young patients. Some studies have shown that 
probiotics can alter the intestinal microflora and reduce the growth of pathogenic 
microorganisms in the intestines of preterm infants, decreasing the incidence of necrotizing 
enterocolitis and sepsis. Moreover, a study performed in rats with immune deficiency has 
shown that the administration of LGG reduced the risk of colonization and sepsis by 
Candida. 
One of our retrospective study, performed in 2002 at the University of Catania TIN, showed 
that supplementation from birth for at least 4-6 weeks of a symbiotic (lactogermine plus 3.5 
x109 ucf / day) decreased the incidence and intensity of gastrointestinal colonization of 
Candida, and subsequently its related infections in a group of preterm infants. 
Another randomized study on 80 preterm infants has confirmed that the administration of 
LGG (at a dose of 6 billion cfu / day) from the first day of life for a period of six weeks 
reduced the fungal enteric colonization with no side effects (Romeo et al, 2011). 
Newborns submitted to greater surgical interventions (esophageal atresia, hernia 
diaframmatica, intestinal malformations) have an increased risk of bacterial and/or mycotic 
infections due to the use of drains, central venous catheter, NPT, persistent nose-gastric 
probe that can be the cause of serious sepsis and pneumonias.  
In a recent study that we presented at ESPHGAN, we demonstrated that surgical infants 
admitted to our NICU and supplemented with probiotics have a reduced risk of bacterial 
and Candida infections and an improved clinical outcome (Figure 1) (Betta et al, 2007) 
In another recently published study on preterm infants, the use of probiotics appeared to be 
effective in the prevention of both bacterial and mycotic infections, in the attenuation of 
gastrointestinal symptoms and in a more rapid weaning from total parenteral nutrition with 
a reduction in the central venous catheter time and the number of days in hospital. These 
results were evident both in a group of preterm newborns and in a group of surgical 
newborn treated with a supplementation of probiotics (Figure 2). 
9. Probiotics and respiratory tract infections (RTI) 
Two studies have examined the effect in adults of a combined multi-strain probiotic and 
multivitamin/mineral supplement containing L. gasseri, B. longum and B. bifidum on the 
incidence, duration and severity of common cold infections and aspects of immune function 
(de Vrese et al, 2006; Winkler et al, 2005). Both studies found a reduction in severity and 
duration, as well as enhanced expression of immune cells, while only Winkler et al. (2005) 
found a reduction in incidence. The major difference between studies is dose—the same 
probiotic strains were used for both, as well as the same assessment methods for the 
illness—suggesting that although the dose used by de Vrese et al. (2006) (5 9 107 CFU) was 
enough to attenuate symptoms and duration, a higher dose such as that used by Winkler et 
al. (2005) (5 9 108 CFU per day) was needed for prevention of infections. The lower dose 
may promote a systemic immune response sufficient to reduce severity and duration but not 
incidence, while the higher dose may stimulate systemic immunity via the mechanism of  
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Fig. 1. The direct introduction of probiotics, that positively influences the intestinal 
microbial population, determining a reduction of more pathogenic species in the bowel 
reservoir, can improve enteral nutrition reducing time of dependence on intravenous 
nutrition and might contribute to a better outcome in high risk newborns.  
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Fig. 2. 
distribution of T and B lymphocytes, primed in the gut, which proliferate to the mucosal-
associated lymphoid tissue (MALT), where the B cells differentiate into immunoglobulin-
producing cells after specific antigenic exposure, leading to an inhibition of colonisation by 
pathogenic strains. 
Olivares et al. (2006) also found an immunostimulatory effect in subjects given a multistrain 
probiotic containing L. gasseri and L. corniformis, compared with a standard yoghurt 
containing S. thermophilus and L. bulgaricus, although this study provides no evidence for 
the efficacy of a greater number of strains, since two non-comparable treatments were used. 
Gluck and Gebbers (2003) investigated colonisation by nasal pathogens and showed a 19% 
reduction in the group given probiotics (L. rhamnosus GG, Bifidobacterium lactis, L. 
acidophilus, S. thermophilus) compared to no reduction with placebo. Despite this 
reduction in colonisation, no data are given as to whether subjects became unwell during 
the study period, making conclusions as to actual health benefits difficult to draw. In a 
similar study, Hatakka et al. (2007) found no effect of a probiotic mixture on incidence and 
duration of otitis and upper respiratory infections on children aged 6 months to 10 years; a 
lower dose than that used by Gluck and Gebbers (2003) may explain the disparity between 
results. It may also be that ingested probiotics have less effect on the aural mucosa 
compared to that on the nasal mucosa, or that the effects are strain-specific. 
In a 7-month study with over 1,000 subjects, Lin et al. (2009) examined the protective effect 
of two single probiotics (L. casei and L. rhamnosus, given individually) and one multi-strain 
mixture containing the 2 lactobacilli and 10 other organisms. Reduced physician visits, as 
well as decreased incidence of bacterial, and viral respiratory disease were seen in all groups 
compared with placebo, but there was no significant difference in effectiveness between the 
preparations even though the multi-strain probiotic was given at a tenfold higher dose than 
the individual strains. However, in the case of prevention of gastro-intestinal tract 
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infections, the probiotic mixture was significantly more effective than the single strains. This 
may be due to the exceptionally high dose given in the multi-strain treatment, resulting in 
larger numbers of probiotic bacteria competing with pathogens for binding sites and or 
nutrients in the gut. 
Another point of interest in this study is that despite large differences in dose, the two single 
strains did not have statistically different effects, suggesting strain-specificity in dose and 
effect for individual species. These data support the theory that supplementation with 
certain multi-strain probiotics can reduce severity, duration, and possibly incidence of RTIs, 
and in the case of Lin et al. (2009) that a multi-strain probiotic may be more effective than a 
single-strain. There is some evidence for immunostimulation, even in cases where illness 
still occurs. Further consistency could be added to this evidence with the establishment, by 
testing varied concentrations of probiotic bacteria, of an optimum dose that prevents 
pathogenic colonisation of the mucosa as well as the incidence and severity of illness. 
Testing this dose with and without vitamin and mineral supplementation may reveal a 
synergy between both types of supplement.  
Further work should be done to determine the relative efficacy of single- and multi-strain 
probiotics in this area. 
10. Conclusion 
The direct introduction of probiotics, can positively influence the intestinal microbial 
population, include a reduction in the bowel reservoir of more pathogenic species, improve 
enteral nutrition, and reduce dependence on intravenous nutrition, favour an increased gut 
mucosal barrier to bacteria and bacterial products, and up regulation in protective 
immunity.  
It is important to establish what probiotic it should be used, the right dosage, the right time 
of use, and furthermore controlled studies should answer to these questions, in order to 
describe specific indications on the type of probiotic that must be used in a specific situation, 
thus better clarifying the structure of the probiotic and its characteristics, selecting the right 
probiotic for each kind of disease.  
It is important to underline that the use of probiotics is safe even at high dosages, without 
any side effect in preterm infants. After birth the rapid development of the intestinal 
microflora regulates all the different gastro-intestinal and immunologic functions that are 
included in the so called mutualism bacteria- host organism. This kind of relationship starts 
from birth and regulate different aspects of the immune system of the newborn.  
Recent epidemiologic data support the hypothesis that in the last 20 years some 
immunologic modification can find a cause in the modification of the intestinal microflora.  
Different therapeutic actions could be potentially able to alter the normal relationship 
between the intestinal microbiota and the host organism. The international medical 
community has to be aware of the increasing importance that initial colonising intestinal 
microflora could have on the health and well-being of the host later in life. It is of great 
importance to know that the initial bacterial colonisation of the neonate appears to play a 
crucial role in inducing immunity in the immature human being, and that a suboptimal 
process could have definite consequences. The optimal early interface between the microbes 
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and the intestinal mucosa of the host may have been somewhat disturbed by modern 
perinatal care. It is fundamental to try to decrease these possible negative influences and to 
discover in the near future the possible means to help manipulate positively the gut 
microbiotia of infants (Rautava, 2007). 
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